Toronto, Ontario June 3, 2021 — Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) a healthcare technology and services company, today announced a rebrand of the company to support its evolution from investment insurer to health-tech disruptor. The new visual identity also unites all assets and subsidiaries under a single Medivolve brand umbrella, further cementing the company’s move toward a powerful, singular mission to create healthier lives. The new branding reflects the long-term strategic vision of Medivolve’s newly appointed CEO, David Preiner, underscored by momentum from a series of recent acquisitions and corporate milestones.
“Medivolve’s rebranding is so much more than a new color palette and logo – it is an opportunity for us to share our renewed vision for the business, for physicians and patients, and the future of healthcare in America,” said David Preiner, CEO of Medivolve. “As we continue to grow, we’re bringing together the pieces to build a SaaS-based health-tech platform that is more valuable than the sum of its parts, and our brand must reflect this model and approach. I’m proud that now, as people all over the country are treated at a Medivolve testing site, they will immediately identify with a brand they can trust to constantly innovate and empower a continuity of care never seen before.”
The company’s new visual identity will be represented on all of its mobile COVID-19, immunology and vaccination testing sites around the United States, where Americans can go for fast, accurate, and accessible testing when and where they need it. Effective immediately, it will discontinue the name “Collections Sites” and operate all assets under the Medivolve corporate name and branding. The rebrand includes a new website, logo, color palette, and refreshed social media channels. Medivolve’s shift to the color red is a purposeful brand decision signifying Medivolve’s passion and energy for improving the future of health management.
As part of this rebrand, Medivolve has created an informative video highlighting its new identity and evolution into an innovative healthcare provider focused on transforming human health management across the United States. Moving forward, Medivolve’s team of medical experts will focus on improving patient care and increasing collaboration with clinicians to offer a more holistic healthcare solution and help create healthier lives.
The rebrand is one of several significant initiatives launched under the company’s new leadership team. In the past several weeks since David Preiner took the helm as CEO, Medivolve announced it has expanded its portfolio of pharmacy acquisitions, with an agreement to acquire Marbella Pharmacy, providing Medivolve immediate access to pharmaceutical distribution throughout the state of California. Medivolve also completed the acquisition of its Electronic Health Record technology, which will serve as its cloud-based platform for improving patient care and increasing collaboration with clinicians.
About Medivolve Inc.
Medivolve Inc. (NEO:MEDV; OTC:COPRF; FRA:4NC) focuses on finding and developing disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and transform human health management. This includes providing convenient and accessible medical services for testing, prevention, and treatment. Medivolve is comprised of a team of renowned global medical and business advisors who are committed to helping fulfill Medivolve’s mission of searching for and investing in breakthrough sciences, technologies, research, or resolutions to empower the betterment of humankind. This panel includes prominent Stanford neurologist and immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, one of North America’s most prominent orthopedic treatment and sports medicine specialists.
For investing inquiries, please contact:
For U.S. media inquiries, please contact:
Sophia Powe
Cautionary Note Regarding Forward-looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the acquisition of the health platform app; the benefits and opportunities related to the health platform app; the pursuit by Medivolve of opportunities; and the merits or potential returns of any such opportunities. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance, or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.